United Therapeutics Co. (NASDAQ:UTHR) Stock Position Decreased by Horizon Investment Services LLC

Horizon Investment Services LLC decreased its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 33.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,244 shares of the biotechnology company's stock after selling 1,596 shares during the period. Horizon Investment Services LLC's holdings in United Therapeutics were worth $1,145,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in UTHR. Pathstone Holdings LLC raised its stake in shares of United Therapeutics by 4.1% during the third quarter. Pathstone Holdings LLC now owns 4,118 shares of the biotechnology company's stock worth $1,476,000 after purchasing an additional 163 shares during the last quarter. Cerity Partners LLC increased its stake in shares of United Therapeutics by 82.1% during the third quarter. Cerity Partners LLC now owns 8,886 shares of the biotechnology company's stock worth $3,184,000 after acquiring an additional 4,005 shares during the period. Daiwa Securities Group Inc. raised its holdings in United Therapeutics by 26.1% during the third quarter. Daiwa Securities Group Inc. now owns 4,119 shares of the biotechnology company's stock worth $1,476,000 after purchasing an additional 852 shares in the last quarter. Fisher Asset Management LLC boosted its holdings in United Therapeutics by 22.3% in the 3rd quarter. Fisher Asset Management LLC now owns 6,305 shares of the biotechnology company's stock valued at $2,259,000 after purchasing an additional 1,150 shares in the last quarter. Finally, FMR LLC boosted its holdings in United Therapeutics by 41.1% in the 3rd quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company's stock valued at $386,168,000 after purchasing an additional 314,004 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.

Remove Ads

United Therapeutics Stock Performance

United Therapeutics stock traded up $5.49 during trading on Wednesday, hitting $312.37. The company's stock had a trading volume of 163,994 shares, compared to its average volume of 449,512. The stock's fifty day moving average is $337.82 and its 200 day moving average is $355.39. United Therapeutics Co. has a 1-year low of $225.62 and a 1-year high of $417.82. The stock has a market capitalization of $14.03 billion, a price-to-earnings ratio of 13.72, a P/E/G ratio of 0.97 and a beta of 0.64.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping the consensus estimate of $6.10 by $0.09. The firm had revenue of $735.90 million during the quarter, compared to analyst estimates of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same quarter in the prior year, the business posted $4.36 earnings per share. On average, research analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

Analyst Ratings Changes

UTHR has been the topic of a number of analyst reports. StockNews.com downgraded United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, February 27th. HC Wainwright restated a "buy" rating and set a $425.00 target price on shares of United Therapeutics in a research report on Thursday, February 27th. Finally, UBS Group increased their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, United Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $388.25.

Insider Activity at United Therapeutics

In related news, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $364.91, for a total value of $3,649,100.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares in the company, valued at approximately $940,373.07. The trade was a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Tommy G. Thompson sold 2,500 shares of the stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $318.80, for a total transaction of $797,000.00. Following the transaction, the director now directly owns 8,480 shares in the company, valued at $2,703,424. The trade was a 22.77 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 72,500 shares of company stock worth $26,134,500. 11.90% of the stock is owned by insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.